Close

Form 8-K OMNICELL, Inc For: Aug 20

August 20, 2015 4:03 PM EDT

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 20, 2015

 

OMNICELL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-33043

 

94-3166458

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

590 E. Middlefield Road
Mountain View, CA  94043

(Address of principal executive offices, including zip code)

 

(650) 251-6100

(Registrant’s telephone number, including area code)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02.             Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 20, 2015, Omnicell, Inc. (the “Company”) announced that Peter Kuipers, age 43, has been appointed Executive Vice President and Chief Financial Officer of the Company, effective August 24, 2015. A press release announcing the change in the Chief Financial Officer position is attached as Exhibit 99.1 hereto and incorporated herein by reference. From December 2014 to May 2015, Mr. Kuipers served as Senior Vice President and Chief Financial Officer of Quantcast Corp., a global technology company that specializes in digital audience measurement and real-time advertising. From May 2013 to December 2014, Mr. Kuipers served as Executive Vice President and Chief Financial Officer of The Weather Company, a media and global technology leader operating The Weather Channel, weather.com, wunderground.com and its professional services division WSI. From September 2009 to April 2013, Mr. Kuipers served in various financial management positions at Yahoo! Inc., a global internet technology company, most recently as Vice President, Finance-Americas. Prior to Yahoo!, Mr. Kuipers served in Senior Financial leadership roles at Altera Corp., General Electric Company and Akzo Nobel. He started his career with Ernst & Young in the Netherlands and Seattle, Washington. Mr. Kuipers received a Master’s Degree in Economics and Business Administration from Maastricht University and is a Chartered Accountant in the Netherlands.

 

Mr. Kuipers will be compensated at an initial base salary of $370,000 per annum, and will receive, upon approval by the Company’s Board of Directors or a committee thereof, (i) an option to purchase up to 37,500 shares of the Company’s Common Stock at an exercise price equal to the fair market value of the Company’s Common Stock on the date of grant, which option shall vest over a four-year period, with a one-year cliff and (ii) an award of 22,500 shares of restricted stock units, which will vest in equal increments every 6 months on June 15 and December 15 over a four-year vesting period.  Mr. Kuipers also will be eligible to participate in the Omnicell 2010 Quarterly Executive Bonus Plan wherein he may receive cash bonuses of up to 50% of his annual base salary based on the achievement of Company and personal performance objectives, subject to changes at the discretion of the Company. Mr. Kuipers may also be eligible to participate, on a pro-rata basis, in the Company’s 2015 Over Achievement Bookings Bonus, to be determined based on the overachievement of the Company’s bookings.

 

In addition, Mr. Kuipers is eligible for certain severance benefits set forth in the Company’s executive Change in Control Agreement and Amended and Restated Severance Benefits Plan, and indemnity protection under an indemnity agreement.

 

In connection with and effective upon Mr. Kuipers’ appointment, Robin G. Seim will step down from his role as the Company’s Chief Financial Officer and will remain as the Company’s Executive Vice President, International and Global Quality and Manufacturing.

 

The description of the compensation arrangements contained herein do not purport to be complete and are qualified in their entirety by reference to the complete text of the offer letter entered into by and between the Company and Mr. Kuipers, including any exhibits thereto, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ending September 30, 2015.

 

2



 

Item 9.01.  Financial Statements and Exhibits.

 

(d)                       Exhibits.

 

Exhibit
Number

 

Description

99.1

 

Press Release entitled “Omnicell Appoints Peter Kuipers as Chief Financial Officer” dated August 20, 2015

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

OMNICELL,  INC.

 

 

 

 

Dated:  August 20, 2015

By:

/s/ Dan S. Johnston

 

 

Dan S. Johnston,

Executive Vice President, Chief Legal & Administrative Officer

 

4



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1

 

Press Release entitled “Omnicell Appoints Peter Kuipers as Chief Financial Officer” dated August 20, 2015

 

5


Exhibit 99.1

 

 

Omnicell Appoints Peter Kuipers as Chief Financial Officer

 

Expansion of Executive Team Adds 20 Years of Financial Expertise within Technology and International Markets

 

Mountain View, Calif., — August 20, 2015 — Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced that Peter Kuipers has joined the company as Executive Vice President, Chief Financial Officer. Mr. Kuipers brings 20 years of financial and business strategy leadership experience in high tech, manufacturing, and international markets. As announced in February, current CFO Rob Seim now completes the transition to his new role as Executive Vice President, International and Global Quality & Manufacturing.

 

“Peter offers a unique blend of industry experience that will make him a valuable addition to our executive team as we look to solidify our position as a leader in the U.S. and expand international opportunities,” said Randall Lipps, Omnicell president, chairman, and CEO. “Peter’s experience will help to advance the company’s focus on growth through differentiated products, new markets, and acquisitions,” he said.

 

Prior to joining Omnicell, Mr. Kuipers served as Senior Vice President and Chief Financial Officer at Quantcast Corporation, a world leader in applying the power of big data and analytics to digital audience measurement and advertising. Previously Mr. Kuipers served as Executive Vice President and CFO at The Weather Company (TWC), operating The Weather Channel, weather.com, wunderground.com and its professional services division WSI.

 

Prior to TWC, Mr. Kuipers served in various financial leadership roles at Yahoo!, including for the company’s largest geographical region as Vice President of Finance for the Americas, a multibillion-dollar business, and led teams responsible for Financial Planning and Analysis, Business Finance, Accounting, and Reporting for the region across multiple product lines and channels. At Yahoo! he also previously served as Vice President of Finance for the Global Products division and as Vice President of Finance for International Regions.

 

Previously Mr. Kuipers served in senior financial leadership roles at Altera Corporation, General Electric Company, and Akzo Nobel. He started his career with Ernst & Young in the Netherlands and Seattle, Washington.

 

He holds a Master’s Degree in Economics and Business Administration from the Maastricht University School of Business and Economics in the Netherlands. He is also a Chartered Accountant in the Netherlands.

 



 

Medication and supply management in health care is undergoing a transformation driven by the power of data and automation technology,” said Mr. Kuipers. “Omnicell is well positioned to provide industry-leading levels of quality and safety to medication management solutions globally and I am proud to be joining one of the industry’s leading innovators.”

 

“As I move into a new role centered around our international markets, I’m pleased to welcome Peter to the role of CFO,” shared Rob Seim. “In an age where international hospitals and health systems are looking to mirror best practices developed by hospitals in the U.S., I’m excited to evaluate and meet the needs of potential customers abroad.”

 

“Since joining us in 2006 Rob has done a terrific job as our CFO, where he has led many of our efforts that resulted in a quadrupling of the revenue and growth of operating income from 6% to 15%. We’re excited about his willingness to take on this expanded role that is core to our continued growth, and appreciate his ongoing commitment and dedication to Omnicell,” said Mr. Lipps.

 

About Omnicell

 

Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

 

More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

 

For more information about Omnicell, Inc. please visit www.omnicell.com.

 

Forward-Looking Statements

 

To the extent any statements contained in this release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to the occurrence of many events outside Omnicell’s control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such statements include, but are not limited to the success of Omnicell’s executive team, Omnicell’s U.S. strategy and Omnicell’s expansion of international opportunities. Risks that contribute to the uncertain nature of the forward-looking statements include our ability to take advantage of the growth opportunities in medication management across the spectrum of healthcare settings

 



 

from long term care to home care, unfavorable general economic and market conditions, risks to growth and acceptance of our products and services, including competitive conversions, and to growth of the clinical automation and workflow automation market generally, the potential of increasing competition, potential regulatory changes, the ability of the company to improve sales productivity to grow product bookings, to develop new products and to acquire and successfully integrate companies. These and other risks and uncertainties are described more fully in Omnicell’s most recent filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Omnicell undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

OMCL-G

 

###

 

Editor’s Notes:

 

1.              All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company’s external website, omnicell.com.

2.              Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.

3.              All other brand or product names may be trademarks or registered trademarks of their respective companies.

 




Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings